Pfizer expects to provide safety data and file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November, delaying any clarity on the vaccine until after the Nov. 3 U.S. presidential election.
The regulatory filing for the vaccine could come as soon as safety data is available in the third week of November, Pfizer said, lifting the company’s shares and the broader U.S. stock market.
The timeline now allows for possible U.S. authorization of a coronavirus vaccine this year, a key step in controlling a pandemic that has killed more than a million and ravaged the global economy.
JUST IN: Pfizer plans to apply for emergency use in the United States for its COVID-19 vaccine candidate being developed along with BioNTech as soon as a safety milestone is achieved in the third week of November https://t.co/REVx95hfT5 pic.twitter.com/g4sZmMbNF5
— Reuters (@Reuters) October 16, 2020
Pfizer said that it would not apply for emergency authorization of its coronavirus vaccine before the third week of November, ruling out President Trump’s assertion that a vaccine would be ready before Election Day. https://t.co/iRUa1ihjKt
— The New York Times (@nytimes) October 16, 2020